Swedish research-based biopharma company BioArctic AB (STO:BIOA-B) announced on Wednesday that it has been granted European patent EP4172199B1 for exidavnemab by the European Patent Office.

Entering into force on 14 May 2025, the new patent offers protection until 2041 with a potential extension to 2046.

Exidavnemab is a monoclonal antibody in development for the treatment of synucleinopathies, including Parkinson's disease and Multiple System Atrophy. The drug targets and removes aggregated alpha-synuclein, which contributes to neuronal damage, with the aim of preserving nerve cell function and slowing disease progression.

This patent expands BioArctic's intellectual property portfolio in Europe and supports its strategy to develop disease-modifying treatments for neurodegenerative conditions.

CEO Gunilla Osswald emphasised the significance of the patent as a reflection of BioArctic's innovation in addressing brain diseases.